| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
African American men and hereditary/familial prostate cancer: Intermediate-risk populations for chemoprevention trials
|
Powell, Isaac J
|
|
2001
|
57 |
4S1 |
p. 178-181
4 p.
|
artikel
|
| 2 |
Agents, biomarkers, and cohorts for chemopreventive agent development in prostate cancer
|
Kelloff, Gary J
|
|
2001
|
57 |
4S1 |
p. 46-51
6 p.
|
artikel
|
| 3 |
Androgen antagonists: Potential role in prostate cancer prevention
|
Trump, Donald L
|
|
2001
|
57 |
4S1 |
p. 64-67
4 p.
|
artikel
|
| 4 |
Angiogenesis as a potential biomarker in prostate cancer chemoprevention trials
|
Ali, Iqbal Unnisa
|
|
2001
|
57 |
4S1 |
p. 143-147
5 p.
|
artikel
|
| 5 |
Antioxidant dietary supplements: Rationale and current status as chemopreventive agents for prostate cancer
|
Fleshner, Neil Eric
|
|
2001
|
57 |
4S1 |
p. 90-94
5 p.
|
artikel
|
| 6 |
Apoptosis as a biomarker in chemoprevention trials
|
Riss, Terry L
|
|
2001
|
57 |
4S1 |
p. 141-142
2 p.
|
artikel
|
| 7 |
A randomized, controlled chemoprevention trial of selenium in familial prostate cancer: Rationale, recruitment, and design issues
|
Costello, Anthony J
|
|
2001
|
57 |
4S1 |
p. 182-184
3 p.
|
artikel
|
| 8 |
Bayesian monitoring of a phase 2 chemoprevention trial in high-risk cohorts for prostate cancer
|
Weiss, Heidi L
|
|
2001
|
57 |
4S1 |
p. 220-223
4 p.
|
artikel
|
| 9 |
Chemoprevention for prostatic carcinoma: The role of flutamide in patients with prostatic intraepithelial neoplasia
|
Alberts, Steven R.
|
|
2001
|
57 |
4S1 |
p. 188-190
3 p.
|
artikel
|
| 10 |
Chemoprevention trials in men with prostate-specific antigen failure or at high risk for recurrence after radical prostatectomy: Application to efficacy assessment of soy protein
|
Bosland, Maarten C
|
|
2001
|
57 |
4S1 |
p. 202-204
3 p.
|
artikel
|
| 11 |
Computer-assisted image analysis–derived intermediate endpoints
|
Boone, Charles W.
|
|
2001
|
57 |
4S1 |
p. 129-131
3 p.
|
artikel
|
| 12 |
Design considerations for efficient prostate cancer chemoprevention trials
|
Lee, J.Jack
|
|
2001
|
57 |
4S1 |
p. 205-212
8 p.
|
artikel
|
| 13 |
Dietary trial in prostate cancer: Early experience and implications for clinical trial design
|
Ornish, Dean M
|
|
2001
|
57 |
4S1 |
p. 200-201
2 p.
|
artikel
|
| 14 |
Early clinical trials of chemopreventive and biologic agents: Designs, populations, and endpoints 1 1 The views expressed in this article do not necessarily represent those of or imply endorsement from the US Food and Drug Administration or the US government. Pursuant to 5 CFR §2635.807(b)(2), federal employees are required to include the preceding statement.
|
Keegan, Patricia
|
|
2001
|
57 |
4S1 |
p. 216-219
4 p.
|
artikel
|
| 15 |
Executive Summary of the National Cancer Institute Workshop: Highlights and recommendations
|
Lieberman, Ronald
|
|
2001
|
57 |
4S1 |
p. 4-27
24 p.
|
artikel
|
| 16 |
Foreword
|
Tindall, Donald J.
|
|
2001
|
57 |
4S1 |
p. vii-
1 p.
|
artikel
|
| 17 |
Histological markers of risk and the role of high-grade prostatic intraepithelial neoplasia
|
Sakr, Wael A
|
|
2001
|
57 |
4S1 |
p. 115-120
6 p.
|
artikel
|
| 18 |
Imaging and prostate cancer chemoprevention:
|
Littrup, Peter J
|
|
2001
|
57 |
4S1 |
p. 121-123
3 p.
|
artikel
|
| 19 |
Introduction
|
Lieberman, Ronald
|
|
2001
|
57 |
4S1 |
p. 1-3
3 p.
|
artikel
|
| 20 |
Magnetic resonance imaging and spectroscopic imaging: Improved patient selection and potential for metabolic intermediate endpoints in prostate cancer chemoprevention trials
|
Kurhanewicz, John
|
|
2001
|
57 |
4S1 |
p. 124-128
5 p.
|
artikel
|
| 21 |
New biologicals for prostate cancer prevention:
|
Pantuck, Allan J
|
|
2001
|
57 |
4S1 |
p. 95-99
5 p.
|
artikel
|
| 22 |
New concepts in the pathology of prostatic epithelial carcinogenesis
|
De Marzo, Angelo M
|
|
2001
|
57 |
4S1 |
p. 103-114
12 p.
|
artikel
|
| 23 |
New molecular approaches for identifying novel targets, mechanisms, and biomarkers for prostate cancer chemopreventive agents
|
Williams, Elizabeth D
|
|
2001
|
57 |
4S1 |
p. 100-102
3 p.
|
artikel
|
| 24 |
New technologies for biomarker analysis of prostate cancer progression: Laser capture microdissection and tissue proteomics
|
Paweletz, Cloud P
|
|
2001
|
57 |
4S1 |
p. 160-163
4 p.
|
artikel
|
| 25 |
Other novel agents: Rationale and current status as chemopreventive agents
|
Tolcher, Anthony W
|
|
2001
|
57 |
4S1 |
p. 86-89
4 p.
|
artikel
|
| 26 |
Oxidative stress in chemoprevention trials
|
DeWeese, Theodore L.
|
|
2001
|
57 |
4S1 |
p. 137-140
4 p.
|
artikel
|
| 27 |
Potential target populations and clinical models for testing chemopreventive agents
|
Klein, Eric A
|
|
2001
|
57 |
4S1 |
p. 171-173
3 p.
|
artikel
|
| 28 |
Preprostatectomy: A clinical model to study stromal-epithelial interactions
|
Lopaczynski, Wlodek
|
|
2001
|
57 |
4S1 |
p. 194-199
6 p.
|
artikel
|
| 29 |
Proapoptotic anti-inflammatory drugs
|
Myers, Charles
|
|
2001
|
57 |
4S1 |
p. 73-76
4 p.
|
artikel
|
| 30 |
Prostate cancer chemoprevention: Strategies for designing efficient clinical trials
|
Lieberman, Ronald
|
|
2001
|
57 |
4S1 |
p. 224-229
6 p.
|
artikel
|
| 31 |
Prostate cancer prevention agent development: Criteria and pipeline for candidate chemoprevention agents
|
Nelson, William G
|
|
2001
|
57 |
4S1 |
p. 56-63
8 p.
|
artikel
|
| 32 |
Prostate cancer prevention strategies using antiproliferative or differentiating agents
|
Walczak, Janet
|
|
2001
|
57 |
4S1 |
p. 81-85
5 p.
|
artikel
|
| 33 |
Prostate-specific antigen and new serum biomarkers for evaluation of chemopreventive agents
|
Partin, Alan W
|
|
2001
|
57 |
4S1 |
p. 132-136
5 p.
|
artikel
|
| 34 |
Prostate-specific antigen–enhanced testing and risk stratification for chemoprevention trials 1 1 The opinions and assertions contained herein are the private views of the author and are not to be construed as reflecting the views of the US Army or the Department of Defense.
|
Moul, Judd W
|
|
2001
|
57 |
4S1 |
p. 174-177
4 p.
|
artikel
|
| 35 |
Quality of Life endpoints in prostate chemoprevention trials
|
Sloan, Jeff A
|
|
2001
|
57 |
4S1 |
p. 235-240
6 p.
|
artikel
|
| 36 |
Randomized, controlled chemoprevention trials in populations at very high risk for prostate cancer: Elevated prostate-specific antigen and high-grade prostatic intraepithelial neoplasia
|
Clark, Larry C
|
|
2001
|
57 |
4S1 |
p. 185-187
3 p.
|
artikel
|
| 37 |
Selective estrogen receptor modulators for the chemoprevention of prostate cancer
|
Steiner, Mitchell S
|
|
2001
|
57 |
4S1 |
p. 68-72
5 p.
|
artikel
|
| 38 |
Sequence databases and microarrays as tools for identifying prostate cancer biomarkers
|
Grouse, Lynette H
|
|
2001
|
57 |
4S1 |
p. 154-159
6 p.
|
artikel
|
| 39 |
Similarities of prostate and breast cancer: Evolution, diet, and estrogens
|
Coffey, Donald S
|
|
2001
|
57 |
4S1 |
p. 31-38
8 p.
|
artikel
|
| 40 |
Standardization, analytical validation, and quality control of intermediate endpoint biomarkers
|
Veltri, Robert W
|
|
2001
|
57 |
4S1 |
p. 164-170
7 p.
|
artikel
|
| 41 |
State of research for prostate cancer: Excerpt∗ from the report of the Prostate Cancer Progress Review Group∗ ∗ For the full report, see: http://osp.nci.nih.gov/prgreports/pprgreport/toc.htm
|
Tindall, Donald J.
|
|
2001
|
57 |
4S1 |
p. 28-30
3 p.
|
artikel
|
| 42 |
Sustaining the effort for cancer prevention
|
Aldigé, Carolyn
|
|
2001
|
57 |
4S1 |
p. 52-55
4 p.
|
artikel
|
| 43 |
Telomerase activity modulation in the prevention of prostate cancer
|
Kim, Nam W.
|
|
2001
|
57 |
4S1 |
p. 148-153
6 p.
|
artikel
|
| 44 |
The molecular pathogenesis of prostate cancer: Implications for prostate cancer prevention
|
Nelson, William G
|
|
2001
|
57 |
4S1 |
p. 39-45
7 p.
|
artikel
|
| 45 |
The Prostate Cancer Prevention Trial: Current status and lessons learned
|
Thompson Jr, Ian M
|
|
2001
|
57 |
4S1 |
p. 230-234
5 p.
|
artikel
|
| 46 |
The role of prostate needle biopsy in evaluation of chemopreventive agents
|
Marks, Leonard S
|
|
2001
|
57 |
4S1 |
p. 191-193
3 p.
|
artikel
|
| 47 |
Trial endpoints for drug approval in oncology: Chemoprevention 1 1 This article is not an official FDA guidance or policy statement. No official support or endorsement by the Food and Drug Administration is intended or should be inferred.
|
Beitz, Julie
|
|
2001
|
57 |
4S1 |
p. 213-215
3 p.
|
artikel
|
| 48 |
Tyrosine kinase inhibitors and signal transduction modulators: Rationale and current status as chemopreventive agents for prostate cancer
|
Bergan, Raymond C
|
|
2001
|
57 |
4S1 |
p. 77-80
4 p.
|
artikel
|
| 49 |
Validation of surrogate endpoint biomarkers in prostate cancer chemoprevention trials
|
Trock, Bruce J
|
|
2001
|
57 |
4S1 |
p. 241-247
7 p.
|
artikel
|
Tijdschrift beschrijving